TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01026064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cantharidin
Description: Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Zithromax (250 mg oral capsule).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02747732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
Description: Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT
Study: NCT01368302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Description: Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Bias Modification Treatment (ABMT)
Description: Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
Study: NCT04778618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
Study: NCT01359748

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference sphygmomanometer
Description: \* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference sphygmomanometer
Description: \* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
Study: NCT02181920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole placebo
Study: NCT02622789

Intervention type: OTHER
Intervention: Pilates Exercises
Description: Pilates method based stability exercise intervention
Study: NCT03688971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omiganan Topical Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT05768594

Intervention type: OTHER
Intervention: Blood sample
Description: After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method

Intervention type: OTHER
Intervention: Blood sample
Description: After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method
Study: NCT01293604

Intervention type: OTHER
Group type: OTHER
Intervention: Daily ingestion of whole grain barley and oats
Description: Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily ingestion of whole grain barley and oats
Description: Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily ingestion of whole grain barley and oats
Description: Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
Study: NCT00269880

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Description: Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
Study: NCT02423135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Description: Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Description: Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
Study: NCT03299816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching DASH group (C-DASH)
Description: Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Shopping DASH group (S-DASH)
Description: Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
Study: NCT02311907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV, over 30 minutes per planned chemotherapy regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Given IV, over 30 minutes per planned chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Given IV, over 15 minutes, immediately before chemotherapy administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV, over 1 or 3 hours, per planned chemotherapy regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Given IV, over 1 or 3 hours, per planned chemotherapy regimen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00109785

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 124 iododeoxyuridine
Study: NCT00835380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine, Purified Inactivated (VAQTA™)
Description: Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
Study: NCT01953757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan diet and vitamin B12 supplement
Description: A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 supplement
Description: A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
Study: NCT03411239

Intervention type: DEVICE
Group type: OTHER
Intervention: Adult esophageal balloon catheter (obc)
Description: Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
Study: NCT02950558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Single injection of ropivacaine immediately prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Single injection of ropivacaine immediately prior to surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
Study: NCT00288691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil (BAY86-5294)
Description: 5mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil (BAY86-5294)
Description: 10mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil (BAY86-5294)
Description: 25mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02892162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional LAAW linear ablation
Description: Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional LAAW linear ablation
Description: Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
Study: NCT03385967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Standard of care 0.5%ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Standard of care 0.5%ropivacaine
Study: NCT00920725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Aspart Insulin [Novolog], Regular Insulin)
Description: Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Aspart Insulin [Novolog], Regular Insulin)
Description: Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Aspart Insulin [Novolog], Regular Insulin)
Description: Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous
Study: NCT01229358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical dressing
Description: Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical dressing
Description: Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
Study: NCT01414842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated sodium profiling in endogenous hemodiafiltration
Description: Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sodium dialysate
Description: Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
Study: NCT01359748

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference sphygmomanometer
Description: \* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.

Intervention type: DEVICE
Group type: OTHER
Intervention: Reference sphygmomanometer
Description: \* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer under test
Description: Electronic Oscillometric method.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer under test
Description: Electronic Oscillometric method.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer under test
Description: Electronic Oscillometric method.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sphygmomanometer under test
Description: Electronic Oscillometric method.
Study: NCT01593969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF/Flax Oil
Description: Ready to Use Therapeutic Food

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF/Flax Oil plus additional Fish Oil
Description: Ready to Use Therapeutic Food

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard RUTF
Description: Standard formulation RUTF given according to National Guidelines
Study: NCT01491633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 140 mg orally, daily in 28 day cycles
Study: NCT02650141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziyinxiehuo Granules
Description: Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zishenqinggan Granules
Description: Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper
Study: NCT03669068

Intervention type: PROCEDURE
Intervention: Gastrointestinal endoscopy
Description: Two separated groups will be included in the registry:~1. Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~2. Patients undergoing elective gastrointestinal endoscopy.

Intervention type: PROCEDURE
Intervention: Gastrointestinal endoscopy
Description: Two separated groups will be included in the registry:~1. Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~2. Patients undergoing elective gastrointestinal endoscopy.
Study: NCT02724085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
Study: NCT03085225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of trabectedin with durvalumab
Description: Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial.
Study: NCT02044250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg 1tab P.O. daily
Study: NCT02724085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
Study: NCT02044250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100\~200mg 1\~2tab P.O. daily
Study: NCT04325854

Intervention type: PROCEDURE
Intervention: I and II level ART procedure
Description: I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
Study: NCT02724085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
Study: NCT03698708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARES Intervention
Description: A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARES Intervention
Description: A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
Study: NCT02604576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC Bromopride 10 mg and Simethicone 80 mg
Description: Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromopride 10 mg
Description: Bromopride 10 mg
Study: NCT02744521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom-based screening intervention
Description: The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
Study: NCT02652936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AF-130
Description: AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: AF-130 matching placebo capsule
Study: NCT02018224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-to-end suturation without augmentation
Description: End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
Study: NCT01222949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim
Description: Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
Study: NCT02018224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-to-end suturation with augmentation.
Description: End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
Study: NCT02026778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ondansetron
Description: The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron-betahistine
Description: The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.